Featured

Status

Health Topics

Any Category
Diseases
Clear Filters

Search Clinical Trials

117 Results
Not Yet Recruiting
Zinc Supplementation in Sickle Cell Disease
The investigators propose a two-arm, double-blinded, Phase II study comparing the effects of two different daily doses of zinc (25 and 40 mg/day) in 34 patients with SCD-SS aged 15-35 …
Baylor Role: Collaborator
Not Yet Recruiting
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This is a dose escalation study. This means that at the beginning, patients will be started on the lowest dose (1 of 4 different levels) of C7R.CD30.CAR-EBVST cells. Once the …
Baylor Role: Lead Sponsor
Recruiting
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
First, patients provide blood for us to make TAA-specific cytotoxic T cells in the lab. The amount of blood to be drawn will be less based on the child's weight …
Baylor Role: Lead Sponsor
Not Yet Recruiting
CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)
Patients will be enrolled to this study in two treatment groups: C7R-EBVSTs without lymphodepletion (Group A) and C7R-EBVSTs with lymphodepletion (Group B). The investigators will enroll patients into group B …
Baylor Role: Lead Sponsor
Withdrawn
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
Earlier, healthy donors gave blood for us to make CD30.CAR-EBVST cells in the laboratory. These cells were grown and frozen and the investigators will select the donor which the investigators …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients
Vascular Ehlers Danlos Syndrome (VEDS) is caused by pathogenic variants of the COL3A1 gene, resulting abnormal Type III collagen protein. This impacts the body's connective tissue and makes people with …
Baylor Role: Lead Sponsor
Recruiting
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
This is a phase I/II study of haploidentical HCT (HHCT) with ex vivo TCRαβ+ and CD19+ depletion using the CliniMACS device in patients with hematological malignancies and non-malignant disorders. HHCT …
Baylor Role: Lead Sponsor
Recruiting
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
The TRICAR-ALL T-cells were made in the laboratory by stimulating the patient's blood with growth factors to make the T cells grow. To get the CD19/CD20/CD22 antibody and 4-1BB to …
Baylor Role: Lead Sponsor
Recruiting
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
The patient will donate blood in order to make C7R-EBV T cells. Depending on how long ago the cells were generated, they have been frozen. To get the C7R to …
Baylor Role: Lead Sponsor
Recruiting
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
The hemolytic uremic syndrome (HUS) is the most serious complication of high-risk Shiga toxin-producing Escherichia coli (STEC) infection and the most common cause of acquired acute kidney injury in otherwise …
Baylor Role: Collaborator